COMMUNIQUÉS West-GlobeNewswire

FibroBiologics to Present at the DealFlow Discovery Conference
20/01/2026
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
InStride Health and The Wharton School Showcase Successful AI Scribe Adoption for Improved Clinician Efficiency and Experience
20/01/2026
Case study highlights how collaboration from clinical and technical teams drive effective, responsible, and scalable AI adoption in behavioral health BOSTON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InStride [...]
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
20/01/2026
SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight , a leader in digital health solutions, today announced a new investment round of $13 million from existing and new investors including Eclipse, General [...]
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
20/01/2026
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va [...]
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
20/01/2026
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies, today announced continued [...]
Radix Health Rebrands as Pivotal Health
20/01/2026
Following rapid adoption of its Independent Dispute Resolution technology, Pivotal Health broadens its mission to help providers achieve fair reimbursement through technology NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- [...]
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
20/01/2026
Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect Biosystems Aspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined [...]
Machina Medical Receives FDA 510(k) Clearance for MFUSE External Bleeding Control Device
20/01/2026
ROSWELL, Ga., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Machina Medical, Corp. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MFUSE, a sterile, single-use medical device [...]
FOXO Technologies Inc. Subsidiary, Big South Fork Medical Center, Expands Clinical Capabilities
20/01/2026
WEST PALM BEACH, FL, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that its critical access-designated acute care hospital, Scott County Community [...]
CorVel Corporation to Host Live Earnings Release Webcast
20/01/2026
FORT WORTH, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its [...]
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™
20/01/2026
LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene [...]
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
20/01/2026
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen ® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with [...]
Avacta Announces Year-end Trading Update
20/01/2026
LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, has [...]
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
20/01/2026
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of [...]
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
20/01/2026
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering [...]
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
20/01/2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its [...]
Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
20/01/2026
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it is [...]
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
20/01/2026
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury Participants to include people with Long COVID who [...]
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
20/01/2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second [...]

Pages